

BIO-TECHNE Corp  
Form 8-K  
April 30, 2019

---

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

---

**FORM 8-K**

---

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): April 30, 2019

---

**BIO-TECHNE CORPORATION**

(Exact Name of Registrant as Specified in its Charter)

Edgar Filing: BIO-TECHNE Corp - Form 8-K

<b>Minnesota</b> (State or Other Jurisdiction of Incorporation)	<b>0-17272</b> (Commission File Number)	<b>41-1427402</b> (I.R.S. Employer Identification Number)
---	--	---

**614**  
**McKinley**  
**Place NE**

**Minneapolis,**  
**MN 55413**  
(Address of  
Principal  
Executive  
Offices) (Zip  
Code)

**(612)**  
**379-8854**  
(Registrant's  
Telephone  
Number,  
Including  
Area Code)

**Not**  
**Applicable**  
(Former  
Name or  
Former  
Address, if  
Changed  
Since Last  
Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: BIO-TECHNE Corp - Form 8-K

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

## **Item 2.02 Results of Operations and Financial Condition**

A copy of the press release issued by Bio-Techne Corporation on April 30, 2019, describing the results of operations for the quarter ended March 31, 2019 and its financial condition as of March 31, 2019, is attached hereto as Exhibit 99.1.

The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

## **Item 8.01 Other Events**

A copy of the press release issued by Bio-Techne Corporation on April 30, 2019, announcing a cash dividend is attached hereto as Exhibit 99.2.

## **Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

99.1 Press Release, dated April 30, 2019, announcing results of operations

99.2 Press Release, dated April 30, 2019, announcing cash dividend.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIO-TECHNE  
CORPORATION

Date: April 30, 2019 By: /s/ Brenda S. Furlow  
Brenda S. Furlow  
Senior Vice President,  
General Counsel and  
Secretary

EXHIBIT INDEX

Exhibit No. Description

- |      |   |
|------|---|
| 99.1 | Press Release, dated April 30, 2019, announcing results of operations |
| 99.2 | Press Release, dated April 30, 2019, announcing cash dividend.        |